Discover
ARTV
Artiva Biotherapeutics, Inc.
10.00
2 x 9.15
1 x 10.79
bid
ask
+
0.85
9.29%
570 @ 04:00 PM
9.70 -0.30 (2.99%)
| Ytd | 133.10% | |
| 1y | 292.16% |
9.04
day range
10.06
2.22
52 week range
14.53
| Open | 9.78 | Prev Close | 9.15 | Low | 9.04 | High | 10.06 | Mkt Cap | 247.17M |
| Vol | 517.98K | Avg Vol | 588.01K | EPS | -3.54 | P/E | -2.82 | Forward P/E | -3.18 |
| Beta | 2.18 | Short Ratio | 20.47 | Inst. Own | 89.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 8.92 | 200-d Avg | 6.19 | 1yr Est | 21.25 |
| Income Statement | |||
| Operating Expenses | 24.43M | ||
| Research and Development Expense | 19.31M | ||
| Selling, General and Administrative Expense | 5.12M | ||
| Operating Income | -24.43M | ||
| Net Income | -23.52M | ||
| Net Income Common Stock | -23.52M | ||
| Net Income Common Stock (USD) | -23.52M | ||
| Consolidated Income | -23.52M | ||
| Earnings per Basic Share | -0.95 | ||
| Earnings per Basic Share (USD) | -0.95 | ||
| Earnings per Diluted Share | -0.95 | ||
| Earning Before Interest & Taxes (EBIT) | -23.52M | ||
| Earning Before Interest & Taxes (USD) | -23.52M | ||
| Weighted Average Shares | 24.68M | ||
| Weighted Average Shares Diluted | 24.68M | ||
| Balance Sheet | |||
| Cash and Equivalents | 21.42M | ||
| Cash and Equivalents (USD) | 21.42M | ||
| Investments | 65.83M | ||
| Investments Current | 65.83M | ||
| Current Assets | 88.74M | ||
| Property, Plant & Equipment Net | 16.30M | ||
| Total Assets | 105.96M | ||
| Debt Current | 3.04M | ||
| Total Debt | 10.26M | ||
| Current Liabilities | 10.88M | ||
| Debt Non-Current | 7.23M | ||
| Total Liabilities | 18.11M | ||
| Accumulated Retained Earnings (Deficit) | -354.06M | ||
| Accumulated Other Comprehensive Income | -18.00K | ||
| Shareholders Equity | 87.85M | ||
| Shareholders Equity (USD) | 87.85M | ||
| Assets Non-Current | 17.22M | ||
| Total Debt (USD) | 10.26M | ||
| Liabilities Non-Current | 7.23M | ||
| Trade and Non-Trade Payables | 2.29M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 666.00K | ||
| Net Cash Flow from Financing | -112.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -5.75M | ||
| Capital Expenditure | -242.00K | ||
| Issuance (Repayment) of Debt Securities | -33.00K | ||
| Net Cash Flow from Investing | 15.32M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 15.56M | ||
| Net Cash Flow from Operations | -20.95M | ||
| Share Based Compensation | 1.59M | ||